A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

NCT01880437 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

Interventions

DRUG: cytarabine
DRUG: vismodegib

Sponsor

Hoffmann-La Roche